ABSTRACT
Background Pneumococcal disease contributes significantly to childhood morbidity and mortality and treatment is costly. Nigeria recently introduced the Pneumococcal Conjugate Vaccine (PCV) to prevent pneumococcal disease. The aim of this study is to estimate health provider and household costs for the treatment of pneumococcal disease in children aged <5 years (U5s), and to assess the impact of these costs on household income.
Methods We recruited U5s with clinical pneumonia, pneumococcal meningitis or pneumococcal septicaemia from a tertiary and a secondary level hospital in Kano, Nigeria. We obtained resource utilisation data from medical records to estimate costs of treatment to provider, and household expenses and income loss data from caregiver interviews to estimate costs of treatment to households. We defined catastrophic health expenditure (CHE) as household costs exceeding 25% of monthly household income and estimated the proportion of households that experienced it. We compared CHE across tertiles of household income (from the poorest to least poor).
Results Of 480 participants recruited, 244 had outpatient pneumonia, and 236 were hospitalised with pneumonia (117), septicaemia (66) and meningitis (53). Median (IQR) provider costs were US$17 (US$14-22) for outpatients and US$272 (US$271-360) for inpatients. Median household cost was US$51 (US$40-69). Overall, 33% of households experienced CHE, while 53% and 4% of the poorest and least poor households, experienced CHE respectively. The odds of CHE increased with admission at the secondary hospital, a diagnosis of meningitis or septicaemia, higher provider costs, and caregiver having a non-salaried job.
Conclusion Provider costs are substantial, and households incur treatment expenses that considerably impact on their income and this is particularly so for the poorest households. Sustaining the PCV programme and ensuring high and equitable coverage to lower disease burden will reduce the economic burden of pneumococcal disease to the healthcare provider and households.
What is already known?
What is already known?
Children <5 years have the highest incidence of pneumonia and invasive pneumococcal disease (IPD) and Nigeria bears the largest burden in sub-Saharan Africa.
Pneumococcal conjugate vaccine (PCV) was introduced in Nigeria in 2016 to reduce the burden of pneumococcal disease
PCV is currently subsidised through Gavi financial support and Nigeria will transition to full self-financing in a few of years
There is no contextual evidence in Nigeria on economic burden of IPD to the health system and society that can support longer term investments in PCV when Gavi co-financing terminates
What are the new findings?
What are the new findings?
Treatment of one hospitalised episode of pneumococcal disease cost on average, US$300 to the provider, and US$83 to the household with significant variation by clinical syndrome and level of care
Overall, a third of the households encountered costs that were catastrophic (i.e., >25% of household income)
Burden of CHE varied by household income tertile ranging from 4% in the least poor households (highest income tertile) to 53% in the poorest households (lowest income tertile)
Despite the short illness duration, pneumococcal disease syndromes result in huge economic costs to providers and households
What do the new findings imply?
What do the new findings imply?
Sustaining the PCV programme and achieving high PCV coverage has the potential of saving resources at both provider and household level
Households are at risk of further impoverishment from catastrophic expenses associated with treatment of pneumococcal disease. This risk can also be significantly reduced by PCV.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding This work was supported through the DELTAS Africa Initiative. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences Alliance for Accelerating Excellence in Science in Africa and supported by the New Partnership for Africa Development Planning and Coordinating Agency with funding from the Wellcome Trust and the UK government. The views expressed in this publication are those of the authors and not necessarily those of AAS, NEPAD Agency, Wellcome Trust or the UK government. IMOA is funded by the United Kingdom Medical Research Council and Department For International Development through a African Research Leader Fellowship. JAGS is funded by a Wellcome Trust Senior Research Fellowship and the NIHR Health Protection Research Unit in Immunisation. JO is funded by the NIHR Global Health Research Unit on Mucosal Pathogens.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Aminu Kano Teaching Hospital Research Ethics Committee Kano State ministry of Health Research Ethics Committee Kenya Medical Research Institute Scientific and Ethical Review Unit London School of Hygiene and Tropical Medicine Observational Interventions Research Ethics Committee
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data supporting findings are included in the manuscript and supplement. Additional data requests can be made to the KEMRI-Wellcome Trust Research Programme Data Governance Committee (dgc@kemri-wellcome.org).
